

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Two parallel prothrombin activator systems in Australian rough-scaled snake, *Tropidechis carinatus*

Structural comparison of venom prothrombin activator with blood coagulation factor X

Md. Abu Reza¹, Sanjay Swarup¹, R. Manjunatha Kini^{1,2}

¹Protein Science Laboratory, Department of Biological Sciences, Faculty of Science, National University of Singapore, Singapore

²Department of Biochemistry and Molecular Biophysics, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia USA

Summary

It is uncommon for similar pathways/systems to be involved in highly divergent functions within single organisms. Earlier, we have shown that trocarin D, a venom prothrombin activator, from the Australian rough-scaled snake *Tropidechis carinatus*, is structurally and functionally similar to the blood coagulation factor Xa (FXa). The presence of a haemostatic system in these snakes implies that they have two parallel prothrombin activating systems: one in the plasma, that participates in the life saving process of blood clotting and the other in their venom, where it acts as a toxin. Here, we report the complete cDNA sequence

encoding the blood coagulation factor X (FX) from the liver of *T. carinatus*. Deduced *T. carinatus* FX sequence shows ~80% identity with trocarin D but ~50% identity with the mammalian FX. Our present study confirms the presence of two separate genes – one each for FX and trocarin D, that code for similar proteins in *T. carinatus* snake. These two genes have different expression sites and divergent uses suggesting that snake venom prothrombin activators have probably evolved by the duplication of the liver FX gene and subsequently marked for tissue-specific expression in the venom gland.

Keywords

Prothrombin activation, factor X, haemostasis, snake venom

Thromb Haemost 2005; 93: 40-7

Introduction

Blood coagulation cascade involves a series of proteolytic activation reactions of several coagulation factors culminating in the formation of a fibrin clot. The activation of the zymogen prothrombin to thrombin is the key reaction in this cascade. This activation is catalyzed by prothrombinase, which is a complex of the vitamin K-dependent serine proteinase FXa and its cofactor factor Va (FVa). The complex is formed in the presence of calcium on the surface of negatively charged phospholipid membranes (1). During the activation of prothrombin, two peptide bonds, Arg₂₇₃-Thr₂₇₄ and Arg₃₂₂-Ile₃₂₃, are cleaved resulting in the formation of mature thrombin (2). FXa alone can activate prothrombin, but at a very slow rate. This activation rate is enhanced by about five orders of magnitude by the formation of the prothrombinase complex (3–5). Therefore, for the activation of prothrombin to thrombin at a physiologically relevant rate,

formation of the prothrombinase complex is a crucial step in blood coagulation.

Apart from the *in vivo* physiological activator FXa, prothrombin is additionally activated by several exogenous factors isolated from various sources, including snake venoms (6, 7). Depending on the cofactor requirements for their optimal activity, exogenous prothrombin activators are classified into four groups, namely groups A, B, C and D (8). Group D prothrombin activators are serine proteinases that cleave the same two peptide bonds in prothrombin (Arg₂₇₃-Thr₂₇₄ and Arg₃₂₂-Ile₃₂₃) and generate mature thrombin (9–11). The prothrombin converting activities of group D members are stimulated by the addition of FVa, Ca²⁺ ions and phospholipids (cofactors of the prothrombinase complex) (9, 12), to the same extent as that of FXa. They form a tight 1:1 complex with FVa in the presence of Ca²⁺ ions and phospholipids (13).

Correspondence to:

R. Manjunatha Kini
Department of Biological Sciences
Faculty of Science, 14 Science Drive 4
National University of Singapore
Singapore 117 453
Tel: + 65-6874-5235, Fax: + 65-6779-2486
E-mail: dbskinim@nus.edu.sg

Received July 20, 2004

Accepted after revision November 11, 2004

Financial support:

This work was supported by the Academic Research Grants from the National University of Singapore

Prepublished online December 8, 2004 DOI: 10.1160/TH04-07-0435

Recently, we purified and characterized several group D prothrombin activators such as trocarin D, hopsarin D, notecarin D, and notanarins D1 and D2 from a number of Australian elapid venoms and determined the amino acid sequences of trocarin D and hopsarin D (9, 11). These studies indicate that group D prothrombin activators from the Australian elapid snakes are true structural and functional homologues of mammalian FXa (9–11). Structurally, they have the same domain architecture as mammalian FXa. The light and heavy chains in these proteins are linked by a single disulfide bond. The light chain contains an N-terminal Gla domain followed by two epidermal growth factor (EGF)-like domains and the heavy chain contains a serine protease domain. The characteristic catalytic triad His₂₃₆, Asp₂₈₂ and Ser₃₇₉, typical for a serine proteinases, is also found conserved in the heavy chain (9–11).

Snakes have their own haemostatic systems, as found in the case of other vertebrates (14). This necessitates the presence of a coagulation factor, factor X (FX) or equivalent protein in its plasma. Thus, there are two prothrombin activating systems in these snakes; a toxin Trocarin D (9) produced in their venom glands, and the other is a haemostatic factor produced in the liver. The difference in their functional roles, therefore, mandates a highly tissue-specific expression of these closely related proteins. Further, their levels of expression are also different: Trocarin D is expressed in the venom gland in high quantities (~1,150 times higher) compared to FX expression in liver (9). Moreover, the regulation of expression of these two proteins is also distinct. In the liver, FX is expressed constitutively (15, 16) and hence produced at a steady state level. In contrast, the expression of venom prothrombin activators is inducible (17, 18); when the venom gland is empty, its expression reaches the maximum, and when the gland is full its expression slows down or stops. Therefore, it is interesting to study the gene structure and regulation of expression of these two closely related proteins with divergent functional roles in the same snake species. As a first step, we have cloned and sequenced a cDNA encoding FX from the liver of *T. carinatus* snake. The deduced amino acid sequence shows that FX produced in the liver is structurally similar to mammalian FX as well as to its own venom prothrombin activator trocarin D. This is the first amino acid sequence of a reptilian coagulation factor. This study will contribute significantly towards the understanding of the structure-function relationships and the mechanism of FXa-mediated prothrombin activation. It will also aid in improving the expression of these proteins, which have a therapeutic potential for the treatment of FX-deficient as well as FVIII and FIX inhibitor patients. Furthermore, it will help us to establish an evolutionary relationship between the physiological prothrombin activator FX in the blood, its venom prothrombin activator and the other FX proteins.

Materials and methods

Liver of *Tropidechis carinatus* was purchased from the Venom Supplies Pty Ltd, Australia. The RNeasy RNA isolation kit, One step RT-PCR kit, Qiaquick gel extraction and PCR purification kit, pDrive cloning kit, QiaPrep mini prep kit were purchased from Qiagen (Valencia, CA, USA), SMART RACE cDNA amplification kit and BD Advantage 2 PCR Enzyme system were

bought from Clontech Laboratories inc (Palo Alto, CA, USA). The ABI PRISM® BigDye® terminator cycle sequencing ready reaction kit was purchased from Perkin Elmer (Foster City, CA, USA). Oligonucleotides were custom synthesized from 1st BASE (Singapore). All other chemicals and reagents were of the purest grade available.

RNA isolation

Total RNA was isolated from the liver tissues of *T. carinatus* using a rotor homogenizer and the RNeasy mini kit. RNA purity and quality was checked by agarose gel (0.8%) electrophoresis. Amount of RNA was quantified spectrophotometrically.

Reverse Transcription – Polymerase Chain Reaction (RT-PCR)

One step RT-PCR was carried out in a final volume of 25 µl using 100 ng of total RNA. FX sequence of mammalian and non-mammalian sources were aligned with that of trocarin D and sense (FXF: 5'-ATTGAAAGGGAATGC-3') and antisense (FXR: 5'-TGCACATCCTTCCCC-3') primers were designed from the most conserved sequence.

The RT-PCR conditions were: reverse transcription at 50°C for 30 min followed by inactivation of reverse transcriptase and activation of *Taq* polymerase at 95°C for 15 min. PCR was performed as follows: 35 cycles of one step each at 94°C for 1 min, 54°C for 45 sec, 72°C for 1 min followed by a final extension at 72°C for 10 min. PCR products were subjected to 1% agarose gel electrophoresis and visualized by ethidium bromide staining. PCR products were purified using Qiagen PCR purification kit according to the manufacturer's instruction.

5'- and 3'- Rapid Amplification of cDNA ends (RACE)

5'- and 3'- RACE libraries were created and amplifications were carried out with Clontech's SMART RACE cDNA amplification kit. Universal primer mix (UPM: 5'-CTAATACGACTCACTATAGGGCA AGCAGTGGTATCAACGCAGAGT-3'; 5'-CTAATACGACTCACTATAGGGC-3') from the SMART RACE kit and gene-specific oligonucleotides were used for amplification. The gene-specific oligonucleotides (GSP1: 5'-TCAGCAGTGGGAAGGCAGGCAGGAACC-3'; GSP2: 5'-GGTTCCTGCCTGCCTTCCCCTGCTGA-3') used for RACE were designed based on the sequence data obtained from RT-PCR product. In each case of 5'- and 3'- RACE, the primers were designed a few hundred bases downstream and upstream of the obtained sequence, respectively, to get an overlap sequence to confirm the RACE sequence with previously obtained sequence. Primers were designed based on the requirements for touchdown PCR (Clontech manual), which requires a T_m ~ 70°C, GC content close to 50–70% and a primer length of 23–30 nucleotides.

Following the initial RACE reactions, 5 µl of the PCR product from each reaction was analyzed in 1% agarose gel. A prominent band with a number of background bands was observed in both the 5'- and 3'- RACE reactions. The remaining PCR products from both the RACE reactions were purified and used as templates for PCR re-amplification reaction. A 2nd set of nested 5'- and 3'- gene specific primers were designed few bases upstream and downstream, respectively, from the 5'GSP1 (5'GSP2: 5'-TGCAGAAGTGCCAACAGTTACCATTG-3') and 3'GSP1

(3'GSP2: 5'-CCTTCCCCTGCTGATTTTGCCAACC-3' oligonucleotide, respectively. These nested gene-specific RACE primers and nested universal primer (Nested UPM: 5'-AAG-CAGTGGTATCAACGCAGAGT-3') from the Clontech's kit were used for nested PCR amplification.

Amplification and cloning of full-length FX cDNA

Based on sequencing of the 5'- and 3'- RACE products, a new set of gene-specific primers were designed to amplify the full length FX cDNA. Amplified PCR product was purified, cloned into pDrive cloning vector and subsequently transformed into DH5 α strain of *E. coli*. Ampicillin (100 mg/ml) and kanamycin (30 mg/ml) were used for selection and 80 mg/ml X-gal and 0.5 ml/l of 100 mM IPTG, respectively, were used for blue and white colony selection.

DNA sequencing was carried out using an ABI PRISM[®] 3100 automated DNA sequencer. All sequencing reactions were carried out using the ABI PRISM BigDye terminator cycle sequencing ready reaction kit according to manufacturer's instructions.

Sequence analysis

Sequence analysis was carried out using BLASTX program at the National Centre for Biotechnology Information website (www.ncbi.nlm.nih.gov). Sequence alignments were carried out using the GeneDoc/DNAMAN program. Prediction of signal peptide and N-glycosylation site was carried out using PSORT and NetGlyc prediction site, respectively, at ExPasy web site (<http://tw.expasy.org/>).

Phylogenetic tree

A neighbour-joining phylogenetic tree for FX sequences along with the prothrombin activators – trocarin D, hopsarin D and pseutarin C (catalytic subunit) was plotted using the software DNAMAN. *Tropidechis* FX was sequenced and all other FX and trocarin D, hopsarin D and pseutarin C (catalytic subunit) sequences were obtained from GenBank. The neighbour-joining tree represents boot strap value after 1000 replicates.

Results

cDNA sequence of FX of *Tropidechis carinatus* liver

The precursor of coagulation factor FX is synthesized in the liver (16). The full length cDNA sequence of FX of *Tropidechis carinatus* liver was obtained by RT-PCR followed by 5'- and 3'-RACE experiments. The sense-primer for RT-PCR was designed based on the sequence of 13–17th amino acid residues of the Gla domain (FXF: LEREC) and the antisense-primer was designed based on the C terminal region (FXR: GEGCA) of the serine protease domain. RT-PCR was carried out using these primers (FXF and FXR), which yielded a PCR product of 1.2 kb size. The cloned PCR product was sequenced and the deduced amino acid sequence showed high similarity with blood coagulation FX.

The 5'- and 3'-RACE libraries were created and amplification of cDNA ends was performed using gene-specific RACE primers (see Methods for detailed primer design). 5'-RACE using antisense oligonucleotide 5'GSP1 and UPM gave a faint PCR band of ~600 bp along with a number of background bands.

This PCR product was reamplified using the second set of nested antisense gene-specific primers 5'GSP2 and NUPM (nested UPM) and a clear band of ~500 bp was obtained. In the 3'-RACE reaction, the primers 3'GSP1 and UPM were used in touchdown PCR. The PCR product was reamplified using the nested 3'GSP2 and NUPM primers to reduce the background. A clear band ~900 bp was obtained upon nested amplification. The 5'- and 3'-RACE products were cloned and sequenced. The cDNA and the deduced amino acid sequences, as expected, showed 100% identity in the overlapping regions obtained from the sequence of the RT-PCR product.

Using the sequence data generated by RACE reactions, new sets of gene-specific primers were designed to generate the full length FX cDNA of *T. carinatus* and to confirm the sequence. Seven positive clones were screened and sequenced from both the directions at least three times. The full length FX cDNA sequence was 1452 bp long and was predicted to encode the FX protein of 483 amino acid residues (Fig. 1). The sequence has been submitted to GenBank (AY651849).

Sequence identity with venom prothrombin activators and other FX

As expected, *T. carinatus* liver FX protein sequence shares high percentage of identity with mammalian and piscine FX sequences as well as venom prothrombin activators. We aligned its sequence with trocarin D, hopsarin D, pseutarin C (catalytic subunit) and other FX sequences (Fig. 2). *T. carinatus* liver FX has similar domain architecture. The light chain has Gla, EGF-I and EGF-II domains and the heavy chain has a serine protease domain. The deduced FXa sequence of *T. carinatus* shows ~80% identity to trocarin D. This data clearly indicates that there are two parallel prothrombin activator systems in *T. carinatus*. The one expressed in the liver is involved in blood clotting process, and the other expressed in the venom glands acts as a toxin. *T. carinatus* liver FX protein sequence (including activation peptide) shares 43–54% identity with FX from all other known sources.

Proteolytic maturation

The precursor of FX includes a signal peptide and a propeptide region. Signal peptides promote translocation and secretion. Upon translocation, signal peptides are cleaved off at signal processing sites. Signal peptides of human as well as other FX are processed at –17 position. According to –3,-1 rule (19) the residue at –3 position of the signal peptide must not be aromatic, charged, large or polar. Since *T. carinatus* FX contains a charged residue (Glu) at –20 position it is most likely that *T. carinatus* FX is processed at –18 position instead of –17. However, the signal peptide prediction algorithm (SignalP 3.0; <http://www.cbs.dtu.dk/services/SignalP/>) predicted the possible processing site between the residue –20 and –21. The propeptide region plays a critical role in the γ -carboxylation of Glu residues in the Gla domain (20) (for details, see below). During maturation, the propeptide region is removed by cleavage at a dibasic site (21, 22). With the exception of human FX (23) all FX including *T. carinatus* FX have a dibasic sequence at the –1 and –2 positions. Subsequently, the single chain precursor is converted into a two-chain mature zymogen FX by two internal cleavages around Arg-

TCATAGCCAGCCCTGAAAGAGACAACACTGTTCTTTCCATCGATAGGCACCATGGCTCCTCAGCTACTCCTCTGCTGATCCTCACTTT	38
<i>M A F Q L L L C L I L T F</i>	-28
-40	
TCTATGGAGTCTCTCAGAGGCTGAAAGTAATGATTCTTAAAGACAAAGTGGCAATAGATTTTTGCAAGAACAACGNGCTAATTC	128
<u>L W S L S E A E S N V F L K S K V A N R F L Q R T K R A N S</u>	3
-21 -20	-1 +1
ACTGTTGAGGAATTTAAAGCTGAAACATTTGAAAGGGAATGCATTGAGGAGAGATGTTCAAAGAAGAAGCCAGGGAGGCATTTGARGA	218
L F E E F K A G N I E R E C I E E R C S K E E A R E A F E D	33
TAACGAGAAACTGAGACCTTCTGGAATGTTTATGTAGATGGGGATCAGTGTTCATCAAACCCCTGTCAATATGGCGGACATGCAAGA	308
N E K T E T F W N V Y V D G D Q C S S N P C H Y G G T C K D	63
TGGCATTGGTAGTTATACCTGTACCTGCTTGGCTGGCTATGAAGGGAAAACTGTCAATATGTCTTATATCAGTCTCGAGATGGACAA	398
G I G S Y T C T C L A G Y E G K N C Q Y V L Y Q S C R V D N	93
TGGTAACCTGTTGGCAACCTGTTCAAACGAAATTCAGTGTTCATGTGCTGAAAGTTACCTTTGGGAGATGATGGGTACT	488
G N C W H F C K P V Q N E I Q C S C A E S Y L L G D D G Y S	123
TTGTGTGCTGGAGGTGACTTTTCATGTGTTAGAAATATAAAGCAAGGAACAAGGGAGGCAAGTCTGCCTGACTTTCAAACAGATTT	578
C V A G G D F S C G R N I K A R N K R E A S L P D F Q T D F	153
TTCTGATGACTATGATGCGATTGATGAAAATAATTTGTTGAAACTCCTACAATTTCTCTGGCTTAGTCCCACTGTGCAGTCCCAGAA	668
S D D Y D A I D E N N F V E T P T N F S G L V P T V Q S Q N	183
TGCAACTTTGCTGAAAAATCTGATAATCCAAGCCCTGATATCAGAGTTGTTAATGAACAGACTGCAAACTGGTGAATTCATGGCA	758
A T L L K K S D N P S P D I R V V N G T D C K L G E C P W Q	213
GGCACTTCTGATAAATGATCAAGGAGATGGGTTTTGTTGGAGAACAAATTTGAGTCCCATCTATGTGCTTACTGAGCCCATGCATTA	848
A L L I N D Q G D G F C G G T I L S P I Y V L T A A H C I N	243
CCAGACCAAGTACATAGAGTTGTTGTTAGGGAAATAGACATATCAAGAAAAAACAACGCTCTCTCTTCTGAGATAAATATATGT	938
Q T K Y I R V V V G E I D I S R K K T G R L L S V D K I Y V	273
GCATCAAAAATTTGTTCTCCACCTATGACTATGATATAGCCCTCATCCAATGAAGACCCCTATCCAGTTCTCTGAAAATGTGGTTCC	1028
H Q K F V P S T Y D Y D I A L I Q M K T P I Q F S E N V V P	303
TGCTGCTCCCACTGCTGATTTTGGCAACCAAGTCCCTCATGAAACAAGATTTTGGCATCGTTAGTGGATTTGGGGCTACTCGAAGAA	1118
A C L P T A D F A N Q V L M K Q D F G I V S G L V P T V Q S Q N	333
AGGACAGACCTTAACACACTTAAAGTCGTTACGCTTCTTATGTGGACAGGCACACCTGCATGCTTTCCAGCAATTTTCCAATTACTCA	1208
G Q T S N T L K V V T L P Y V D R H T C M L S S N F P I T Q	363
AAATGTTCTGTGCTGATAAATAACTCTGCTCAAGATGCATGCCAGGAGACAGTGGGGGGCCCAATCACTGCATCAGAGATAC	1298
N M F C A G Y N T L P Q D A C Q G D S G G P H I T A Y R D T	393
CCACTTTACTGGGATATCAGCTGGGGGAAGGATGTCACAGACAGGCAANATGGTGTACACAAAAGTGTCCAGATTATCCT	1388
H F I T G I I S W G E G C A Q T G K Y G A Y T K V S R F I L	423
TTGGATAAAAAGTAATGCGCTTAAGCTACCCATACAGATCAGCACCAGTGGGCTCAAAAATCATCCAGTGGCATATTTTCATGC	1478
W I K R I M R L K L P S T E S S T G R L ***	443
1452	
AGCAATAATGCATTTGGGTTAGAACATTCATGATATCCACTTTGGTTCAGAACTCTTCAGATGTAGTGCCACTTTTAAATATAACATCAA	1568
GTCATGTAGCTTTCCTATTTATCGAGAGCTTTTTTCTCTGTTAATCCCTCTGGCACATAGAAATGAGTAGACTATTTTCATTTTCAGC	1658
TCTGTCTCTGTGTACCTATCTTTTACGACCTTTTCTAAGATTTATACAGTTTGTAAATTTAATCCTTCAAATGAGAGCTCAGCAG	1748
GAATATTTGGTCCCTTTGTAATACAACCTCCAGTCCCTTGAGACCATCAGTGGGTTAATCAAGAGTAGTGCCCAACTGGGTAAATCAGCT	1838
GAATGTTTTCAAATTTAATTTACCCAAACAGAAGCAGAGGTCRAAACCAACCTTCACTACTGTTGCTTCTACTTCTATGGAGGAGGG	1928
ATTAGGGAGCTCATAAACTTTGCTCTACGAAATCCAACACTTCATGTCAAAAATTTCTTGAAGAAAGTGAACAGAAATCTGTATTTCCCA	2018
AAATGTTATCCACTCGCTGCTCACATTTTGGGTTATTTTGTGTGATCAAAATTTCCAGTACAGAGATCTGATTGAGATGATCACTAAC	2108
TGGGTTATAGGAACAGAATAAAGTATATTTCAAAAAAAAAAAAAAAAAAAAAA	2168

Figure 1: Complete nucleotide sequence of cDNA encoding blood coagulation factor FX of *Tropidechis carinatus*. The amino acid sequence is shown in single letter code beneath the nucleotide sequence. Nucleotide (in italics) and amino acid numbers are shown in the column on the right. Numbering starts with Ala1 at the amino terminus of the light chain of the mature zymogen. The putative signal peptide is underlined (from -40 to -21) and the propeptide is doubly underlined (from -20 to -1). The sequences of the propeptide and internal cleavage sites are boxed. Putative γ -carboxylated Glu residues are in boldface and underlined.

Xaa-Lys/Arg-Arg and release of a short peptide (21, 22). In venom homologues, trocarin D and hopsarin D, the cleavage appears to be after the Arg-Asn-Lys as their light chains end with KARNK (9, 11). Since a similar sequence is also found in *T. carinatus* FX, it may be processed similarly.

Proteolytic activation

The zymogen FX has negligible procoagulant activity (3-5). When required, it is activated to FXa by TF-VIIa (24, 25) or IXa-VIIIa (24, 26) complexes through a proteolytic cleavage at Arg₁₉₄-Ile₁₉₅ (human FX numbering) and removal of the activation peptide. The proteolytic activation site is conserved in *Tropidechis* FX. The size of activation peptide segment varies considerably among different FX proteins. Its size appears to reduce during evolution; fish FX have the longest activation peptides (54-66 residues), whereas mammals have the shortest (49-52 residues). However, reptilian *Tropidechis* FX has intermediate size of 57 residues. Interestingly, the enzymatic subunit (which is structurally similar to group D prothrombin activators

and FX) of pseutarin C, a group C prothrombin activator from snake venom, has the shortest activation peptide of 27 residues (27).

Post translational modifications

Disulfide bonds

Disulfide bonds are important in determining the protein folding and overall three dimensional structure and stability of the protein. All the 24 cysteine residues are conserved in *Tropidechis* FX which form 12 disulfide bonds; one in the Gla domain (Cys₁₇, Cys₂₂), three in EGF-I domain (Cys₅₀-Cys₆₂, Cys₅₆-Cys₇₁, Cys₇₃-Cys₈₂), three in EGF-II domain (Cys₉₀-Cys₁₀₁, Cys₉₇-Cys₁₁₀, Cys₁₁₂-Cys₁₂₅), four in the catalytic domain (Cys₂₁₅-Cys₂₂₀, Cys₂₃₆-Cys₂₅₂, Cys₃₇₈-Cys₃₉₂ and Cys₄₀₃-Cys₄₃₁) and one inter-chain disulfide bond between Cys₁₃₃-Cys₃₃₀ (Fig. 3). In hopsarin D, the first cysteine residue (11) (Cys₂₁₅) and in Zebrafish the last cysteine residue (28) (Cys₄₃₁) on the heavy chain is found to be replaced by serine and valine respectively. Hopsarin D has 10-fold lower activity compared to trocarin D

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.




Figure 2: Alignment of deduced amino acid sequence of *Tropidechis carinatus* FX with sequences of mammalian and non-mammalian FX and groups C and D prothrombin activators. Alignment was carried out using the software DNAMAN; gaps (-) are introduced for optimal alignment. “X” indicates sequence not known. Conserved residues (100%) are shaded in black, 80% conserved ones in dark grey and 60% conserved ones in light grey. Pseutarin C catalytic subunit is shown as “Pseutarin_C”. The sequences have been taken from the following sources: Tropidechis FX (this paper): AY651849; Human FX: P00742; Bovine FX: P00743; Murine FX: AAH03877; Rat FX: NP 058839; Rabbit FX: AF003200; Zebrafish FX: AAM88343; trocarin D from *Tropidechis carinatus*: P81428, hopsarin D from *Hoplocephalus stephensi*: P83370; Pseutarin C catalytic subunit: AY260939.

and FXa (11). It is not clear whether the absence of the 11th disulfide linkage results in the lower catalytic activity.

γ-Carboxylation

γ-Carboxylation is one of the distinct characteristics of vitamin K- dependent serine proteinases. Gla residues confer calcium binding properties on proteins (29, 30). In the presence of Ca²⁺ ions, these proteins undergo conformational changes and bind to membranes via a Ca²⁺ bridge to express procoagulant activity (31–35). γ-Carboxylation is catalyzed by a specific carboxylase. The recognition site for γ-carboxylase is located in the propeptide region. Two critical residues shown to be important for the recognition of carboxylase, Phe₋₁₆ and Ala₋₁₀ (36), are conserved in *T. carinatus* FX. There are 12 Glu residues in the Gla domain of *T. carinatus* FX; all of them are at identical positions compared to trocarin D and hopsarin D. We have shown that all except Glu₃₈ residues are carboxylated in trocarin D (9). Based on the homology (Fig. 4), we propose that only the first 11 Glu residues are carboxylated in *T. carinatus* FX. First ten of Gla residues are conserved in all the FX sequences. The 11th Gla is not con-

served in human and two piscine FX, whereas the 12th Gla is not conserved in reptilian FX. Either the location of 11th Gla or the presence of 12th Gla does not appear to severely affect the activity.

β-hydroxylation

The invariant Asp₆₄ of the mature FX protein (homology numbering, Fig. 2) in human is posttranslationally hydroxylated to β-hydroxyaspartic acid (Hya) in EGF-I domain (37). This Asp₆₄ is conserved in *T. carinatus* FX. Even the conserved consensus sequence Cys-Xaa-Hya-Xaa-Xaa-Xaa-Xaa-Tyr/Phe-Xaa-Cys-Xaa (38, 39) surrounding the Hya residue is also conserved in *Tropidechis* FX. But in spite of having this consensus sequence, trocarin D is not hydroxylated at this position (11). It is not known whether Asp₆₄ in *T. carinatus* FX is β-hydroxylated and if so, then what is its biological significance (11).

Glycosylation

Glycosylation is known to play an important role in the stability as well as folding (40). In general, glycosylation has been

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.




Figure 3: Schematic representation of the domain architecture of *T. carinatus* FXa. Similar to the human FXa and trocarin D, *T. carinatus* FXa contains a light chain and a heavy chain linked by a disulfide bond. Unlike Human FXa, *T. carinatus* FX and trocarin D are O- and N-glycosylated both in the light and heavy chains, respectively.

thought to play a role in the stabilization of protein conformation and protection from proteolysis (41, 42) as well as cell-surface recognition phenomenon in multicellular organisms (43). Wang et al. (44) have also shown that glycosylation enhances the thermal stability of proteins. Although the zymogen FX is a glycoprotein, all carbohydrate moieties are found on the peptide segment that is removed during activation (40, 45). These carbohydrate moieties are important for the activation of zymogen FX by

both intrinsic and extrinsic tenase complexes (45, 46). Besides the two potential N-glycosylation sites on the activation peptide, we found one potential O-glycosylation site at Ser₅₂ position of light chain and N-glycosylation site on the Asn₂₅₄ residue of the heavy chain of *Tropidechis* FX (Fig. 3). Interestingly, the group D prothrombin activator trocarin D from the same snake and hopsarin D from *Hoplocephalus stephensi* have similar O- and N-glycosylation sites (9, 11). We have determined the structure of carbohydrate moieties linked at these sites in trocarin D (47). All the non-mammalian FX have a similar potential N-glycosylation site at this position in the heavy chain. However, in case of mammals, glycosylation is restricted to the activation peptide only such that active FXa is not glycosylated. This finding suggests that the N-glycosylation site exists in FXa of the lower vertebrates but not in mammalian FXa. This finding provides a new insight in terms of evolution of the coagulation factors.

Discussion

So far, a number of procoagulant proteins from snake venoms have been purified and characterized (12, 48–51). Rosing and his co-workers first isolated and purified prothrombin activators from *Notechis scutatus scutatus* and *Oxyuranus scutellatus scutellatus* venoms (14, 48). Their studies showed that the prothrombin activation by the *Notechis* activator was stimulated by the presence of FVa, phospholipids and Ca²⁺. Thus, the protein described by them functionally resembles FXa with respect to catalytic properties. Recently, we isolated and characterized trocarin D from the venom of *T. carinatus* (Australian rough-scaled snake) (9). As mentioned in the Introduction, trocarin D as well as other group D prothrombin activators are structurally and functionally similar to blood coagulation FXa (9–11).

The initial blood coagulation cascade is believed to have evolved over 450 million years ago (52) before the divergence of tetrapods and teleosts and the complete/total cascade was formed by gene duplication and diversification (53, 54). Coagulation cascades similar to that of mammals exist even in non-mammalian vertebrates, such as amphibians, birds, fishes and reptiles (14, 28, 55–58). We have shown that *Tropidechis* snake plasma treated with FX-activating proteinase from Russell's viper venom (RVV-X) leads to the activation of a protease which cleaves FXa specific chromogenic substrate (58). This observation clearly indicates the presence of a zymogen similar to FX in snake plasma, which plays a crucial role in hemostasis.

In this paper, we determined the full length cDNA sequence of plasma prothrombin activator- liver FX from *T. carinatus*. Structurally, *T. carinatus* FX shows all the characteristic features

Figure 4: γ -Carboxylation of Glu residues in the Gla domain. The residues that are carboxylated are shaded in black. Phe-16 and Ala-10, shaded in grey, are known to play critical role in the enzyme recognition site for γ -carboxylation.

	-16	-10	+1	20	39	
Tropidechis_FX:	ELKSKVANRFLQRTKRANSLV	EEFKAGNI	ERECIC	EEFRCSKEE	BARDAEFDNEKTTET	
Human_FX :	PIRREQANNILARVTRANSFL	EEFKAGNI	ERECIC	EEFRCSKEE	BARDAEFDNEKTTET	
Bovine_FX :	ELPRDQAHRVLQARRANSLV	EEFKAGNI	ERECIC	EEFRCSKEE	BARDAEFDNEKTTET	
Murine_FX :	FINRERANNVLARTRANSFEE	EEFKAGNI	ERECIC	EEFRCSKEE	BARDAEFDNEKTTET	
Rat_FX :	FINRERANNVLQIRRRANSFEE	EEFKAGNI	ERECIC	EEFRCSKEE	BARDAEFDNEKTTET	
Zebrafish_FX :	FLNTRDANQVLIRQRANSLV	EEFKAGNI	ERECIC	EEFRCSKEE	BARDAEFDNEKTTET	
Hopsarin_D :	-----SNSLFE	IRP	GNIE	RECI	EEFKCSKEE	BARDAEFDNEKTTET
Trocarin_D :	-----SNSLFE	IRP	GNIE	RECI	EEFKCSKEE	BARDAEFDNEKTTET




Figure 5: Phylogenetic relationships among FX proteins.

Sources of the sequences are the same as in Figure 2. The neighbour-joining tree represents bootstrap values after 1000 replicates. Nodes with confidence value greater than 70% are indicated. Tree was plotted using the software DNAMAN.

including the domain architecture and 24 conserved cysteines found in other FX sequences as well as its venom prothrombin activator trocarin D. It shares >50% identity with other FXs, but much higher (~80%) identity with its venom protein trocarin D. As observed in other known FX proteins, it contains a 40-residue long pre-pro leader sequence, which is removed during maturation (16, 59). The sites for signal peptide processing, proteolytic maturation and activation are conserved in *T. carinatus* FX. In terms of posttranslational modifications such as γ -carboxylation, *N*- and *O*-glycosylation, it is closer to its venom prothrombin activator, trocarin D rather than to other FX proteins. All FX proteins are glycosylated. Interestingly, activated FXa proteins in lower vertebrates (fishes and reptiles) retain the carbohydrate moieties as they are located on the light and heavy chains, whereas in the case of mammalian FX proteins the glycosylated segment is removed during activation. Our preliminary studies on the de-glycosylation of trocarin D indicated that glycosylation plays a critical role in its stability and de-glycosylation results in autolytic destruction. Thus glycosylation in acti-

vated FXa in mammals might have been eliminated during the course of evolution probably to make FXa short-lived after activation.

The phylogenetic tree generated by neighbor joining method (Fig. 5) shows that all the vertebrate FX proteins have evolved from a common ancestor. The venom prothrombin activators, such as trocarin D and hopsarin D, seem to have branched recently. We hypothesize that group D prothrombin activators have evolved by duplication of liver FX gene and subsequently marked for tissue-specific expression in the venom gland. Thus liver FX is 'modified' and recruited to be used as an offensive weapon in capturing the prey.

In this paper we have shown that FX is synthesized in *T. carinatus* liver and is probably released into its plasma. As shown earlier (58), RVV-X activates a plasma protein resulting in the formation of FXa-like activity. Taken together, we believe that this protein plays a crucial role in the hemostasis of *T. carinatus*. In a separate study, we have shown that the prothrombin activator, trocarin D is structurally and functionally similar to mammalian FXa (9). This venom protein acts as toxin and induces cyanosis and death in mice. Therefore, *T. carinatus* has two similar but diverse prothrombin activating enzymes that are encoded by two different genes. Despite similar structural and catalytic properties, these two proteins are involved in distinctly divergent functions within the same organism. This is a very rare phenomenon. These two closely related proteins are encoded by two separate genes with different outcomes of regulation, possibly resulting from different regulatory controls. Further studies to understand tissue-specific expression and transcriptional control of these two proteins will be of great interest. Such studies may help us to express and produce large amounts of recombinant FX and related proteins that have therapeutic potential. We are currently attempting to decipher the subtle differences between these two closely related proteins to understand the functional dichotomy. Finally, these studies may also aid in clarifying the molecular details of the prothrombinase complex formation.

Acknowledgement

We thank Dr. Prakash Kumar of the Department of Biological Sciences, National University of Singapore for his critical comments during the revision of the manuscript.

References

- Suttie JW, Jackson CM. Prothrombin structure, activation, and biosynthesis. *Physiol Rev* 1977; 57: 1–70.
- Mann KG. The assembly of blood clotting complexes on membranes. *Trends Biochem Sci* 1987; 12: 229–33.
- Rosing J, Tans G, Govers-Riemslog JW, et al. The role of phospholipids and factor Va in the prothrombinase complex. *J Biol Chem* 1980; 255: 274–83.
- Mann KG, Krishnaswamy S, Lawson JH. Surface-dependent hemostasis. *Semin Hematol* 1992; 29: 213–26.
- van Rijn JL, Govers-Riemslog JW, Zwaal RF, et al. Kinetic studies of prothrombin activation: effect of factor Va and phospholipids on the formation of the enzyme-substrate complex. *Biochemistry* 1984; 23: 4557–64.
- Markland FS, Jr. Snake venoms. *Drugs* 1997; 54 Suppl 3: 1–10.
- Hutton RA, Warrell DA. Action of snake venom components on the haemostatic system. *Blood Rev* 1993; 7: 176–89.
- Manjunatha KR, Morita T, Rosing J. Classification and nomenclature of prothrombin activators isolated from snake venoms. *Thromb Haemost* 2001; 86: 710–11.
- Joseph JS, Chung MC, Jeyaseelan K, et al. Amino acid sequence of trocarin, a prothrombin activator from *Tropicdehis carinatus* venom: its structural similarity to coagulation factor Xa. *Blood* 1999; 94: 621–31.
- Joseph JS, Kini RM. Snake venom prothrombin activators homologous to blood coagulation factor Xa. *Haemostasis* 2001; 31: 234–40.
- Rao VS, Joseph JS, Kini RM. Group D prothrombin activators from snake venom are structural homologues of mammalian blood coagulation factor Xa. *Biochem J* 2003; 369(Pt 3): 635–42.
- Rosing J, Tans G. Structural and functional properties of snake venom prothrombin activators. *Toxicon* 1992; 30: 1515–27.
- Tans G, Govers-Riemslog JW, van Rijn JL, et al. Purification and properties of a prothrombin activator from the venom of *Notechis scutatus scutatus*. *J Biol Chem* 1985; 260: 9366–72.
- Archer RK. The Haemostatic Mechanism In Man And Other Animals. In: Macfarlane RG, editor. *Blood coagulation in non-human vertebrates*. Academic Press, 1970: 121–32.

15. Bahnak BR, Howk R, Morrissey JH, et al. Steady state levels of factor X mRNA in liver and Hep G2 cells. *Blood* 1987; 69: 224–30.
16. Miao CH, Leytus SP, Chung DW, et al. Liver-specific expression of the gene coding for human factor X, a blood coagulation factor. *J Biol Chem* 1992; 267: 7395–01.
17. Rotenberg D, Bamberger ES, Kochva E. Studies on ribonucleic acid synthesis in the venom glands of *Viper palaestinae* (Ophidia, Reptilia). *Biochem J* 1971; 121: 609–12.
18. Paine MJ, Desmond HP, Theakston RD, et al. Gene expression in *Echis carinatus* (carpet viper) venom glands following milking. *Toxicon* 1992; 30: 379–86.
19. von Heijne G. A new method for predicting signal sequence cleavage sites. *Nucleic Acids Res* 1986; 14: 4683–90.
20. Ulrich MM, Furie B, Jacobs MR, et al. Vitamin K-dependent carboxylation. A synthetic peptide based upon the gamma-carboxylation recognition site sequence of the prothrombin propeptide is an active substrate for the carboxylase in vitro. *J Biol Chem* 1988; 263: 9697–02.
21. Bristol JA, Furie BC, Furie B. Propeptide processing during factor IX biosynthesis. Effect of point mutations adjacent to the propeptide cleavage site. *J Biol Chem* 1993; 268: 7577–84.
22. Wasley LC, Rehemtulla A, Bristol JA, et al. PACE/furin can process the vitamin K-dependent pro-factor IX precursor within the secretory pathway. *J Biol Chem* 1993; 268: 8458–65.
23. Fung MR, Campbell RM, MacGillivray RT. Blood coagulation factor X mRNA encodes a single polypeptide chain containing a prepro leader sequence. *Nucleic Acids Res* 1984; 12: 4481–92.
24. Lawson JH, Mann KG. Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation. *J Biol Chem* 1991; 266: 11317–27.
25. Wesselschmidt R, Likert K, Huang Z, et al. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. *Blood Coagul Fibrinolysis* 1993; 4: 661–69.
26. Ahmad SS, Rawala-Sheikh R, Walsh PN. Components and assembly of the factor X activating complex. *Semin Thromb Hemost* 1992; 18: 311–23.
27. Rao VS, Swarup S, Kini RM. The catalytic subunit of psutarin C, a group C prothrombin activator from the venom of *Pseudonaja textilis*, is structurally similar to mammalian blood coagulation factor Xa. *Thromb Haemost* 2004; 92: 509–21.
28. Jagadeeswaran P, Sheehan JP. Analysis of blood coagulation in the zebrafish. *Blood Cells Mol Dis* 1999; 25: 239–49.
29. Padmanabhan K, Padmanabhan KP, Tulinsky A, et al. Structure of human des(1–45) factor Xa at 2.2 Å resolution. *J Mol Biol* 1993; 232: 947–66.
30. Mizuno H, Fujimoto Z, Atoda H, et al. Crystal structure of an anticoagulant protein in complex with the Gla domain of factor X. *Proc Natl Acad Sci U S A* 2001; 98: 7230–34.
31. Nelsestuen GL, Broderius M, Martin G. Role of gamma-carboxyglutamic acid. Cation specificity of prothrombin and factor X-phospholipid binding. *J Biol Chem* 1976; 251(22): 6886–93.
32. Nelsestuen GL, Zytkevich TH, Howard JB. The mode of action of vitamin K. Identification of gamma-carboxyglutamic acid as a component of prothrombin. *J Biol Chem* 1974; 249: 6347–50.
33. Prendergast FG, Mann KG. Differentiation of metal ion-induced transitions of prothrombin fragment 1. *J Biol Chem* 1977; 252: 840–50.
34. Borowski M, Furie BC, Bauminger S, et al. Prothrombin requires two sequential metal-dependent conformational transitions to bind phospholipid. Conformation-specific antibodies directed against the phospholipid-binding site on prothrombin. *J Biol Chem* 1986; 261: 14969–75.
35. Soriano-Garcia M, Padmanabhan K, de Vos AM, et al. The Ca²⁺ ion and membrane binding structure of the Gla domain of Ca-prothrombin fragment 1. *Biochemistry* 1992; 31: 2554–66.
36. Furie B, Furie BC. Molecular basis of vitamin K-dependent gamma-carboxylation. *Blood* 1990; 75: 1753–62.
37. Drakenberg T, Fernlund P, Roepstorff P, et al. beta-Hydroxyaspartic acid in vitamin K-dependent protein C. *Proc Natl Acad Sci U S A* 1983; 80: 1802–06.
38. Stenflo J, Lundwall A, Dahlback B. beta-Hydroxyasparagine in domains homologous to the epidermal growth factor precursor in vitamin K-dependent protein S. *Proc Natl Acad Sci U S A* 1987; 84: 368–72.
39. McMullen BA, Fujikawa K, Kisiel W, et al. Complete amino acid sequence of the light chain of human blood coagulation factor X: evidence for identification of residue 63 as beta-hydroxyaspartic acid. *Biochemistry* 1983; 22: 2875–84.
40. Fujikawa K, Titani K, Davie EW. Activation of bovine factor X (Stuart factor): conversion of factor Xalpha to factor Xbeta. *Proc Natl Acad Sci U S A* 1975; 72: 3359–63.
41. Walsh MT, Watzlawick H, Putnam FW, et al. Effect of the carbohydrate moiety on the secondary structure of beta 2-glycoprotein. I. Implications for the biosynthesis and folding of glycoproteins. *Biochemistry* 1990; 29: 6250–57.
42. Rudd PM, Joao HC, Coghil E, et al. Glycoforms modify the dynamic stability and functional activity of an enzyme. *Biochemistry* 1994; 33: 17–22.
43. Kobata A. Structures and functions of the sugar chains of glycoproteins. *Eur J Biochem* 1992; 209: 483–01.
44. Wang C, Eufemi M, Turano C, et al. Influence of the carbohydrate moiety on the stability of glycoproteins. *Biochemistry* 1996; 35: 7299–307.
45. Inoue K, Morita T. Identification of O-linked oligosaccharide chains in the activation peptides of blood coagulation factor X. The role of the carbohydrate moieties in the activation of factor X. *Eur J Biochem* 1993; 218: 153–63.
46. Sinha U, Wolf DL. Carbohydrate residues modulate the activation of coagulation factor X. *J Biol Chem* 1993; 268: 3048–51.
47. Joseph JS, Valiyaveetil M, Gowda DC, et al. Occurrence of O-linked Xyl-GlcNAc and Xyl-Glc disaccharides in trocarnin, a factor Xa homolog from snake venom. *J Thromb Haemost* 2003; 1: 545–50.
48. Speijer H, Govers-Riemslog JW, Zwaal RF, et al. Prothrombin activation by an activator from the venom of *Oxyuranus scutellatus* (Taipan snake). *J Biol Chem* 1986; 261: 13258–67.
49. Hasson SS, Theakston RD, Harrison RA. Cloning of a prothrombin activator-like metalloproteinase from the West African saw-scaled viper, *Echis ocellatus*. *Toxicon* 2003; 42: 629–34.
50. Gao R, Manjunatha KR, Gopalakrishnakone P. A novel prothrombin activator from the venom of *Microphechis ikaheka*: isolation and characterization. *Arch Biochem Biophys* 2002; 408: 87–92.
51. Silva MB, Schattner M, Ramos CR, et al. A prothrombin activator from *Bothrops erythromelas* (jara-raca-da-seca) snake venom: characterization and molecular cloning. *Biochem J* 2003; 369: 129–39.
52. Davidson CJ, Tuddenham EG, McVey JH. 450 million years of hemostasis. *J Thromb Haemost* 2003; 1: 1487–94.
53. Jiang Y, Doolittle RF. The evolution of vertebrate blood coagulation as viewed from a comparison of puffer fish and sea squirt genomes. *Proc Natl Acad Sci U S A* 2003; 100: 7527–32.
54. Doolittle RF, Feng DF. Reconstructing the evolution of vertebrate blood coagulation from a consideration of the amino acid sequences of clotting proteins. *Cold Spring Harb Symp Quant Biol* 1987; 52: 869–74.
55. Hackett E, Hann C. Slow clotting of reptile bloods. *J Comp Pathol* 1967; 77: 175–80.
56. Rowley AF, Hill DJ, Ray CE, et al. Haemostasis in fish—an evolutionary perspective. *Thromb Haemost* 1997; 77: 227–33.
57. Frost CL, Naude RJ, Oelofsen W, et al. Comparative blood coagulation studies in the ostrich. *Immunopharmacology* 1999; 45: 75–81.
58. Joseph JS, Chung MC, Mirtschin PJ, et al. Effect of snake venom procoagulants on snake plasma: implications for the coagulation cascade of snakes. *Toxicon* 2002; 40: 175–83.
59. Racchi M, Watzke HH, High KA, et al. Human coagulation factor X deficiency caused by a mutant signal peptide that blocks cleavage by signal peptidase but not targeting and translocation to the endoplasmic reticulum. *J Biol Chem* 1993; 268: 5735–40.